ViiV planning submissions this year for two-drug HIV regimen

By Brian Moy, Assistant Editor | Mar 15, 2019 | 5:44 PM GMT

ViiV said it plans to submit regulatory applications this year for a once-monthly two-drug regimen comprising cabotegravir and Johnson & Johnson's Edurant rilpivirine to treat HIV-1 infection.

ViiV Healthcare Ltd. (Brentford, U.K.)